“Phase 2 Confirmatory Study of Cemiplimab (350 Mg IV Q3W) in Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Study 1540 Group 6”. SKIN The Journal of Cutaneous Medicine 7, no. 2 (March 13, 2023): s175. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/1999.